13 : 00 – 13 : 45

Registration onsite and Lunch

13 : 45 – 13 : 50

Session Opening and Introduction

Breast Cancer Session

speaker-1

Dr. Omalkhair Aboalkhair

speaker-2

Dr. Aisha Alharbi

speaker-3

DR. Ibrahim Madkhali

speaker-4

Dr. Majid Aljahel

speaker-5

Dr. Faress Husseini

speaker-6

Sadal Refai

13 : 50 – 14 : 00

Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).

speaker-1

Dr. Shereef Elsamany

14 : 00 – 14 : 10

Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.

speaker-1

Dr. Esam Murshid

14 : 10 – 14 : 20

3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).

speaker-1

Dr Metab Alfohaidi

14 : 20 – 14 : 30

Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC)

speaker-1

Dr. Abokhair Algahmi

14 : 30 – 14 : 40

EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: Updated results by duration of prior CDK4/6i in metastatic setting (San Antonio 2022) .

speaker-1

Dr. Taleb Bohlaiqa

14 : 40 – 15 : 10

Abstracts Discussion (Practice changing Abstracts)

speaker-1

Prof. Joseph Gligorov 🇫🇷

15 : 10 – 15 : 25

Q&A and Panel Discussion

15 : 25 – 15 : 55

Satellite symposium (menarini) Topic: ER+HER- Advanced Breast cancer unmet Needs & Novel Endocrine Therapies

ChairPerson : Dr. Essam Murshid
Speaker : Dr. Nuhad K. Ibrahim

speaker-1

Dr. Esam Murshid

speaker-2

Nuhad K. Ibrahim 🇺🇸

15 : 55 – 16 : 25

Satellite symposium (Lilly) Topic: Updates on CDK4/6 in the Management of EBC

Chair Person : Dr. Taleb Bohlaiaqh
Speaker : Andreas Markis (UK)

speaker-1

Dr. Taleb Bohlaiqa

speaker-2

Dr. Andreas Markis 🇬🇧

16 : 25 – 17 : 05

Satellite Symposium (Novartis) Topic: Updates in Early Breast Cancer Management

ChairPerson :Dr. Taleb Bohlaiaqh
Speaker :Dr. Essam Murshid

speaker-1

Dr. Taleb Bohlaiqa

speaker-2

Dr. Esam Murshid

17 : 05 – 17 : 20

Break

Lung Cancer Session

speaker-1

Dr. Marwan Alhajeili

speaker-2

Prof. Ahmed Baddeeb

speaker-3

Dr. Waleed Baja

speaker-4

Dr. Hatem Majoub

speaker-5

Dr. Muneera Al Hussaini

speaker-6

Dr. Bandar Almutairi

17 : 25 – 17 : 35

Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC).

speaker-1

Dr. Mervat Mahrous

17 : 35 – 17 : 45

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

speaker-1

Dr. Ahmed A. Refae

17 : 45 – 17 : 55

The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer with KRAS G12C mutation (WJOG14821L).

speaker-1

Dr. Abdullah Al Twigri

17 : 55 – 18 : 05

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

speaker-1

Dr. Shadi AlKhayyat

18 : 05 – 18 : 15

SWOG S1929: Phase II randomized study of maintenance atezolizumab (A) versus atezolizumab + talazoparib (AT) in patients with SLFN11 positive extensive stage small cell lung cancer (ES-SCLC).

speaker-1

Dr. Ahmed AlWabari

18 : 15 – 18 : 45

Abstracts Discussion (Practice changing Abstracts)

speaker-1

Dr. Santiago Viteri 🇪🇸

18 : 45 – 19 : 00

Polling + Q&A

speaker-1

Dr. Mervat Mahrous

19 : 00 – 19 : 30

Satellite symposium(Pfizer) First line treatment of ALK+ mNSCLC

ChairPerson : Dr. Taleb Bohlaiaqh
Speaker : Dr. Mervat Mahrous

speaker-1

Dr. Taleb Bohlaiqa

speaker-2

Dr. Mervat Mahrous

19 : 30 – 20 : 00

Satellite symposium(BMS) Local experience with dual IO blockade in Frontline mNSCLC

ChairPerson : Dr. Abdullah Altwairgi
Speaker : Dr. Waleed Alselwi

speaker-1

Dr. Abdullah Al Twigri

speaker-2

Dr. Waleed Alselwi

20 : 00

Panel Discussion and Wrap up & Closing

Gala DINNER

GU Cancer Session

speaker-1

Dr. Abdullah AlSharm

speaker-2

Dr. Abdulaziz Al Hamad

speaker-3

Dr. Faisal Albadainah

speaker-4

Dr. Eman bukhari

speaker-5

Dr. Omar Altaib

09 : 30 – 09 : 35

Welcome Day2 Session Opening and Introduction

09 : 35 – 09 : 45

Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk

speaker-1

Dr. Nedal Bukhari

09 : 45 – 09 : 55

Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.

speaker-1

DR. Amin ElTigani

09 : 55 – 10 : 05

Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial

speaker-1

Dr. Faisal Azam

10 : 05 – 10 : 15

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426

speaker-1

Dr. Fahad Bin Shamsa

10 : 15 – 10 : 25

Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.

speaker-1

Dr. Mubarak Almansour

10 : 25 – 10 : 40

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design

speaker-1

Dr. Yasser Bahader

10 : 40 – 10 : 50

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.

speaker-1

Dr. Rula AlMofti

11 : 05 – 11 : 30

Abstract Discussion (Practice changing Abstracts)

speaker-1

DR. Guillermo de Velasco 🇪🇸

11 : 30 – 11 : 45

Q&A and Panel Discussion

11 : 45 – 12 : 15

Satellite symposium (Janssen) Topic: Updates on the management of mHSPC

ChairPerson : Dr. Essam Murshid
Speaker : Dr. Aisha Alharbi

12 : 15 – 12 : 45

Satellite symposium (BMS) Topic:Treating Gastric cancer today. Clinical practice in KSA

ChairPerson : Dr. Ashwaq Alolayan
Speaker : Dr. Kanan Alshammari

12 : 45 – 13 : 30

Prayer & LUNCH Break

GI cancer Session

speaker-1

Dr. Hoda Mokhtar

speaker-2

Dr. Mohamed Alfayaz

speaker-3

Dr. Hazem Alotabi

speaker-4

Dr. Waleed Alselwi

speaker-5

Dr. Ahmed Mostafa

speaker-6

Dr. Ghanim Almotiri

13 : 30 – 13 : 40

PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

speaker-1

Dr. Fahad Almokbal

13 : 40 – 13 : 50

Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial.

speaker-1

Dr. Ahmed Alshehri

13 : 50 – 14 : 00

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial

speaker-1

Dr. Kanan Alshamari

14 : 00 – 14 : 10

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

speaker-1

Dr. Safwan Bakhsh

14 : 10 – 14 : 20

Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study

speaker-1

Dr. Mohamed Algarni

14 : 20 – 14 : 30

Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial

14 : 30 – 14 : 40

NRG/RTOG 1112: Randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC).

speaker-1

Dr. Ashwaq Alolayan

14 : 40 – 15 : 10

Abstract Discussion (What is Practice changing one)

speaker-1

Dr. Gerlad Prager 🇦🇹

15 : 15 – 15 : 30

POLLS/Q&A

speaker-1

Dr. Mervat Mahrous

Panel Discussion and Wrap up & Closing